AU2001291738A1 - "Slow release" pharmaceutical compositions comprising lithium carbonate - Google Patents
"Slow release" pharmaceutical compositions comprising lithium carbonateInfo
- Publication number
- AU2001291738A1 AU2001291738A1 AU2001291738A AU9173801A AU2001291738A1 AU 2001291738 A1 AU2001291738 A1 AU 2001291738A1 AU 2001291738 A AU2001291738 A AU 2001291738A AU 9173801 A AU9173801 A AU 9173801A AU 2001291738 A1 AU2001291738 A1 AU 2001291738A1
- Authority
- AU
- Australia
- Prior art keywords
- lithium carbonate
- formulation
- lithium
- oad
- granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 title claims abstract description 32
- 229910052808 lithium carbonate Inorganic materials 0.000 title claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
- 239000007931 coated granule Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 46
- 239000008187 granular material Substances 0.000 claims description 20
- 239000001856 Ethyl cellulose Substances 0.000 claims description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims description 5
- 239000007903 gelatin capsule Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 230000003001 depressive effect Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 230000002607 hemopoietic effect Effects 0.000 claims description 2
- 201000002364 leukopenia Diseases 0.000 claims description 2
- 231100001022 leukopenia Toxicity 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 39
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 25
- 229910052744 lithium Inorganic materials 0.000 description 25
- 230000036470 plasma concentration Effects 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229940075894 denatured ethanol Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031281 lithium carbonate 300 mg Drugs 0.000 description 1
- 229940033335 lithium carbonate 600 mg Drugs 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 238000009136 lithium therapy Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI200A001868 | 2000-08-10 | ||
| IT2000MI001868A IT1318677B1 (it) | 2000-08-10 | 2000-08-10 | Composizione farmaceutica contenente litio carbonato. |
| ITMI20010299 ITMI20010299A1 (it) | 2001-02-14 | 2001-02-14 | Composizione farmaceutica contenente litio carbonato |
| ITMI2001A000299 | 2001-02-14 | ||
| PCT/EP2001/009054 WO2002011740A2 (fr) | 2000-08-10 | 2001-08-06 | Compositions pharmaceutiques renfermant du carbonate de lithium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001291738A1 true AU2001291738A1 (en) | 2002-02-18 |
Family
ID=26332755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001291738A Abandoned AU2001291738A1 (en) | 2000-08-10 | 2001-08-06 | "Slow release" pharmaceutical compositions comprising lithium carbonate |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6989159B2 (fr) |
| EP (1) | EP1315480B1 (fr) |
| JP (1) | JP2004505923A (fr) |
| CN (1) | CN1230150C (fr) |
| AT (1) | ATE295154T1 (fr) |
| AU (1) | AU2001291738A1 (fr) |
| BR (1) | BR0113070A (fr) |
| CA (1) | CA2417930A1 (fr) |
| DE (1) | DE60110814D1 (fr) |
| EA (1) | EA200300128A1 (fr) |
| WO (1) | WO2002011740A2 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20010220A1 (it) * | 2001-02-05 | 2002-08-05 | Valpharma Sa | Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno |
| US20040241252A1 (en) * | 2003-05-29 | 2004-12-02 | Abney Christopher Charles | Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same |
| WO2005102366A2 (fr) * | 2004-04-19 | 2005-11-03 | Philip Maxwell Satow | Combinaisons de lithium et utilisations associees |
| WO2008022472A1 (fr) * | 2006-08-23 | 2008-02-28 | Heinz Forster | Composition pharmaceutique |
| WO2008067409A2 (fr) * | 2006-11-28 | 2008-06-05 | Polyplus Battery Company | Électrodes au lithium protégées pour l'administration de médicament par électrotransport |
| WO2009006349A2 (fr) * | 2007-06-29 | 2009-01-08 | Polyplus Battery Company | Dispositifs, procédés et ensembles médicament-électrode pour électrotransport |
| US20090069740A1 (en) * | 2007-09-07 | 2009-03-12 | Polyplus Battery Company | Protected donor electrodes for electro-transport drug delivery |
| FR2999426B1 (fr) * | 2012-12-13 | 2015-01-02 | Flamel Tech Sa | Forme orale multiparticulaire a liberation immediate d'au moins un compose actif, comprenant des particules enrobees resistantes au broyage. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2016922B (en) * | 1978-02-17 | 1982-08-18 | Delandale Lab Ltd | Sustained release lithium carbonate tables |
| US4264573A (en) | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| SE509029C2 (sv) * | 1988-08-16 | 1998-11-30 | Ss Pharmaceutical Co | Långtidsverkande diklofenak-natriumpreparat |
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| HU206824B (en) | 1990-08-24 | 1993-01-28 | Biogal Gyogyszergyar | Process for the production of a table crystallizing in the monoclinic system, which contains light-, heat-, and moisture- sensitive active agents |
| US6365196B1 (en) * | 1997-10-03 | 2002-04-02 | Smithkline Beecham Corporation | Controlled release solid dosage forms of lithium carbonate |
-
2001
- 2001-08-06 DE DE60110814T patent/DE60110814D1/de not_active Expired - Lifetime
- 2001-08-06 AU AU2001291738A patent/AU2001291738A1/en not_active Abandoned
- 2001-08-06 US US10/343,997 patent/US6989159B2/en not_active Expired - Fee Related
- 2001-08-06 EP EP01971873A patent/EP1315480B1/fr not_active Expired - Lifetime
- 2001-08-06 BR BR0113070-6A patent/BR0113070A/pt not_active IP Right Cessation
- 2001-08-06 JP JP2002517075A patent/JP2004505923A/ja active Pending
- 2001-08-06 CN CNB018139760A patent/CN1230150C/zh not_active Expired - Fee Related
- 2001-08-06 CA CA002417930A patent/CA2417930A1/fr not_active Abandoned
- 2001-08-06 AT AT01971873T patent/ATE295154T1/de active
- 2001-08-06 WO PCT/EP2001/009054 patent/WO2002011740A2/fr not_active Ceased
- 2001-08-06 EA EA200300128A patent/EA200300128A1/ru unknown
-
2005
- 2005-05-05 US US11/122,742 patent/US20050208154A1/en not_active Abandoned
-
2007
- 2007-10-29 US US11/978,703 patent/US20080124390A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE295154T1 (de) | 2005-05-15 |
| DE60110814D1 (de) | 2005-06-16 |
| WO2002011740A2 (fr) | 2002-02-14 |
| JP2004505923A (ja) | 2004-02-26 |
| US20080124390A1 (en) | 2008-05-29 |
| CA2417930A1 (fr) | 2002-02-14 |
| WO2002011740A3 (fr) | 2002-04-18 |
| US6989159B2 (en) | 2006-01-24 |
| BR0113070A (pt) | 2003-07-08 |
| US20050208154A1 (en) | 2005-09-22 |
| CN1446082A (zh) | 2003-10-01 |
| EP1315480B1 (fr) | 2005-05-11 |
| EP1315480A2 (fr) | 2003-06-04 |
| US20040013746A1 (en) | 2004-01-22 |
| EA200300128A1 (ru) | 2003-08-28 |
| CN1230150C (zh) | 2005-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080124390A1 (en) | Pharmaceutical compositions containing lithium carbonate | |
| US4784858A (en) | Controlled release tablet | |
| DK173082B1 (da) | Præparat til forsinket frigivelse af et lægemiddel fra et Matrix-System | |
| CN100444843C (zh) | 法舒地尔盐酸盐缓释口服制剂 | |
| US6117453A (en) | Solid compositions containing polyethylene oxide and an active ingredient | |
| US6048547A (en) | Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient | |
| JPH0611699B2 (ja) | 固体薬剤調製物及びその製造法 | |
| HUP0202338A2 (en) | Pharmaceutical composition containing fenofibrate and preparation method | |
| HUE028204T2 (en) | Pharmaceutical compositions containing the active ingredient nilotinib or a salt thereof | |
| JP4856843B2 (ja) | 新規フェノフィブラート錠剤 | |
| JP5026426B2 (ja) | ７−クロロ−Ｎ，Ｎ，５−トリメチル−４−オキソ−３−フェニル−３，５−ジヒドロ−４Ｈ−ピリダジノ［４，５−ｂ］インドール−１−アセトアミドのアモルファス固体分散体 | |
| EP1929997A1 (fr) | Formules d'oxcarbazépine | |
| KR100767271B1 (ko) | 사퀴나비르 메실레이트 경구 투여 형태 | |
| JP3037393B2 (ja) | 経口投与用固形薬剤の製造方法 | |
| KR20160027078A (ko) | 라놀라진 및 드로네다론의 제약 조성물 | |
| JP7264711B2 (ja) | レベチラセタム含有医薬組成物の製造方法 | |
| JP3992764B2 (ja) | イブジラスト含有持続性製剤およびその製法 | |
| RU2247561C1 (ru) | Комбинированная фармацевтическая композиция с противотуберкулёзным действием | |
| JP2023529001A (ja) | 結晶形のラベキシモドを含む経口製剤 | |
| BRPI0412707B1 (pt) | processo para preparo de partículas contendo itraconazol na forma de um co-precipitado e partículas | |
| WO2008141751A2 (fr) | Compositions pharmaceutiques comprenant de l'oxcarbazépine | |
| JP2022545822A (ja) | チダミド医薬組成物、その調製方法及びその適用 | |
| KR20160096178A (ko) | 리튬 공동 투여 없이 고칼륨혈증을 치료하기 위한 규산지르코늄 | |
| KR100706267B1 (ko) | 타크롤리무스의 가용화 방법 및 그로부터 제조된 가용화제제 | |
| JP2008230967A (ja) | 医薬組成物 |